Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus-I-negative Donors for Adult T-Cell Leukemia/Lymphoma

Retrospective Analysis of Data from the Japan Marrow Donor Program

Koji Kato, Yoshinobu Kanda, Tetsuya Eto, Tsuyoshi Muta, Hisashi Gondo, Shuichi Taniguchi, Tsunefumi Shibuya, Atae Utsunomiya, Takakazu Kawase, Shunichi Kato, Yasuo Morishima, Yoshihisa Kodera, Mine Harada

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were 49.5%, 49.2%, 18.6%, and 32.3%, respectively. Multivariate analysis identified recipient age as an independent prognostic factor for OS (P = .044). Patients age ≥50 years who showed nonremission at transplantation tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors.

Original languageEnglish
Pages (from-to)90-99
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 1 2007
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Human T-lymphotropic virus 1
Homologous Transplantation
Bone Marrow Transplantation
Japan
Bone Marrow
Tissue Donors
Unrelated Donors
Survival
Mortality
Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents
Disease-Free Survival
Disease Progression
Multivariate Analysis
Transplantation
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus-I-negative Donors for Adult T-Cell Leukemia/Lymphoma : Retrospective Analysis of Data from the Japan Marrow Donor Program. / Kato, Koji; Kanda, Yoshinobu; Eto, Tetsuya; Muta, Tsuyoshi; Gondo, Hisashi; Taniguchi, Shuichi; Shibuya, Tsunefumi; Utsunomiya, Atae; Kawase, Takakazu; Kato, Shunichi; Morishima, Yasuo; Kodera, Yoshihisa; Harada, Mine.

In: Biology of Blood and Marrow Transplantation, Vol. 13, No. 1, 01.01.2007, p. 90-99.

Research output: Contribution to journalArticle

Kato, Koji ; Kanda, Yoshinobu ; Eto, Tetsuya ; Muta, Tsuyoshi ; Gondo, Hisashi ; Taniguchi, Shuichi ; Shibuya, Tsunefumi ; Utsunomiya, Atae ; Kawase, Takakazu ; Kato, Shunichi ; Morishima, Yasuo ; Kodera, Yoshihisa ; Harada, Mine. / Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus-I-negative Donors for Adult T-Cell Leukemia/Lymphoma : Retrospective Analysis of Data from the Japan Marrow Donor Program. In: Biology of Blood and Marrow Transplantation. 2007 ; Vol. 13, No. 1. pp. 90-99.
@article{26d52cf762964b809179249a355e753c,
title = "Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus-I-negative Donors for Adult T-Cell Leukemia/Lymphoma: Retrospective Analysis of Data from the Japan Marrow Donor Program",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were 49.5{\%}, 49.2{\%}, 18.6{\%}, and 32.3{\%}, respectively. Multivariate analysis identified recipient age as an independent prognostic factor for OS (P = .044). Patients age ≥50 years who showed nonremission at transplantation tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors.",
author = "Koji Kato and Yoshinobu Kanda and Tetsuya Eto and Tsuyoshi Muta and Hisashi Gondo and Shuichi Taniguchi and Tsunefumi Shibuya and Atae Utsunomiya and Takakazu Kawase and Shunichi Kato and Yasuo Morishima and Yoshihisa Kodera and Mine Harada",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2006.09.002",
language = "English",
volume = "13",
pages = "90--99",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus-I-negative Donors for Adult T-Cell Leukemia/Lymphoma

T2 - Retrospective Analysis of Data from the Japan Marrow Donor Program

AU - Kato, Koji

AU - Kanda, Yoshinobu

AU - Eto, Tetsuya

AU - Muta, Tsuyoshi

AU - Gondo, Hisashi

AU - Taniguchi, Shuichi

AU - Shibuya, Tsunefumi

AU - Utsunomiya, Atae

AU - Kawase, Takakazu

AU - Kato, Shunichi

AU - Morishima, Yasuo

AU - Kodera, Yoshihisa

AU - Harada, Mine

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were 49.5%, 49.2%, 18.6%, and 32.3%, respectively. Multivariate analysis identified recipient age as an independent prognostic factor for OS (P = .044). Patients age ≥50 years who showed nonremission at transplantation tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were 49.5%, 49.2%, 18.6%, and 32.3%, respectively. Multivariate analysis identified recipient age as an independent prognostic factor for OS (P = .044). Patients age ≥50 years who showed nonremission at transplantation tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors.

UR - http://www.scopus.com/inward/record.url?scp=33845975998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845975998&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2006.09.002

DO - 10.1016/j.bbmt.2006.09.002

M3 - Article

VL - 13

SP - 90

EP - 99

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -